Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 912 participants.
Also called NCT07092709
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 912 participants
- Registry
-
NCT07092709
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07092709. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-14 (actual); primary completion 2028-09-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users
- Acronym
- PEARL-DOAC
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Record details
- Record id
cardio:ct-nct07092709- Content hash
ef49b1dfb5cc1148b600aee7da1a588a613549ff321446489c14d3fe477c2ad7